FASN Antibody

中文名稱：

FASN兔多克隆抗體
貨號：

CSB-PA13179A0Rb
規格：

￥440
圖片：
IHC image of CSB-PA13179A0Rb diluted at 1:100 and staining in paraffin-embedded human breast cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated SP system.

IHC image of CSB-PA13179A0Rb diluted at 1:100 and staining in paraffin-embedded human liver cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a biotinylated secondary antibody and visualized using an HRP conjugated ABC system.

Immunofluorescence staining of Hela cells with CSB-PA13179A0Rb at 1:100, counter-stained with DAPI. The cells were fixed in 4% formaldehyde, permeabilized using 0.2% Triton X-100 and blocked in 10% normal Goat Serum. The cells were then incubated with the antibody overnight at 4°C. The secondary antibody was Alexa Fluor 488-congugated AffiniPure Goat Anti-Rabbit IgG(H+L).
其他：

產品詳情
產品評價
相關產品
靶點詳情

產品詳情

產品名稱：

Rabbit anti-Homo sapiens (Human) FASN Polyclonal antibody
Uniprot No.：

P49327
基因名：

FASN
別名：

[Acyl-carrier-protein] S acetyltransferase antibody; [Acyl-carrier-protein] S malonyltransferase antibody; 3-hydroxypalmitoyl-[acyl-carrier-protein] dehydratase antibody; 3-oxoacyl-[acyl-carrier-protein] reductase antibody; 3-oxoacyl-[acyl-carrier-protein] synthase antibody; Enoyl-[acyl-carrier-protein] reductase antibody; FAS antibody; FAS_HUMAN antibody; FASN antibody; Fatty acid synthase antibody; MGC14367 antibody; MGC15706 antibody; OA 519 antibody; Oleoyl-[acyl-carrier-protein] hydrolase antibody; SDR27X1 antibody; Short chain dehydrogenase/reductase family 27X member 1 antibody
宿主：

Rabbit
反應種屬：

Human
免疫原：

Recombinant Human Fatty acid synthase protein (2155-2495AA)
免疫原種屬：

Homo sapiens (Human)

標記方式：

Non-conjugated

本頁面中的產品，FASN Antibody (CSB-PA13179A0Rb)，的標記方式是Non-conjugated。對于FASN Antibody，我們還提供其他標記。見下表：

標記方式	貨號	產品名稱	應用
HRP	CSB-PA13179B0Rb	FASN Antibody, HRP conjugated	ELISA
FITC	CSB-PA13179C0Rb	FASN Antibody, FITC conjugated
Biotin	CSB-PA13179D0Rb	FASN Antibody, Biotin conjugated	ELISA

克隆類型：

Polyclonal
抗體亞型：

IgG
純化方式：

>95%, Protein G purified
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
產品提供形式：

Liquid
應用范圍：

ELISA, IHC, IF

推薦稀釋比：

Application	Recommended Dilution
IHC	1:20-1:200
IF	1:50-1:200

Protocols：

ELISA Protocol
Immunohistochemistry (IHC) Protocol
Immunofluorescence (IF) Protocol
儲存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產品評價

靶點詳情

功能：

Fatty acid synthetase is a multifunctional enzyme that catalyzes the de novo biosynthesis of long-chain saturated fatty acids starting from acetyl-CoA and malonyl-CoA in the presence of NADPH. This multifunctional protein contains 7 catalytic activities and a site for the binding of the prosthetic group 4'-phosphopantetheine of the acyl carrier protein ([ACP]) domain.
基因功能參考文獻：
1. Evaluation of FAS/FASL polymorphisms can predict lack of response to BCG immunotherapy and prevent the loss of valuable time before such alternative treatments as early cystectomy are initiated. PMID: 29453645
2. FASN-induced S6 kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in diffuse large B-cell lymphoma. PMID: 29483509
3. HIV-1 infection increases intracellular levels of fatty acid synthase (FASN). Despite the requirement of FASN for nascent virion production, FASN activity was not required for intracellular Gag protein production, indicating that FASN dependent de novo fatty acid biosynthesis contributes to a late step of HIV-1 replication PMID: 28962653
4. Findings showed that FASN is upregulated in colorectal cancer cell lines that overexpress PGC-1alpha and indicated that FASN expression may enhance cancer cell proliferation by regulating antioxidant enzyme production and resistance to ROS-induced apoptosis. Further data provided evidence that FASN expression was regulated indirectly by PGC-1alpha. PMID: 29130104
5. Repression of FAS mRNA expression is the consequence of feedback inhibition of FAS expression by long chain fatty acyl-CoAs, which are formed by FACL3 during its upregulation by vitamin D3 in prostate cancer cells. PMID: 15556626
6. analysis of the expression of fatty acid synthase, Ki-67 and p53 in squamous cell carcinomas of the larynx PMID: 18949744
7. Fatty acid synthase (FASN) mRNA and protein overexpression were associated with unfavorable clinicopathologic factors and poor outcomes. PMID: 28442505
8. KRAS is associated with activation of ERK2, induction of FASN, and promotion of lipogenesis. PMID: 28400509
9. The study has shown that the high frequency of FASN expression in intraepithelial neoplasia (hPIN)and cancer and no expression in most structures of benign hyperplasia make it possible to use this protein as an additional marker in the differential diagnosis of prostatic neoplasms. PMID: 28418352
10. FASN inhibition/knockdown significantly increased the susceptibility of cisplatin-resistant cells to NK cell cytotoxicity. PMID: 29306075
11. FASN has a role in leucine deprivation-inhibited proliferation and apoptosis of human breast cancer cells PMID: 27579768
12. HER2-FASN lipogenic axis delineates a group of breast cancer patients that might benefit from treatment with therapeutic regimens containing FASN inhibitors PMID: 27714708
13. FASN expression is down-regulated by miR-15a and miR-16-1 in breast cancer cells, regulating cell proliferation. PMID: 27713175
14. These findings implicate Spot14 as a direct protein enhancer of FASN catalysis in the mammary gland during lactation when maximal MCFA production is needed. PMID: 24771867
15. High FASN expression is associated with prostate cancer growth. PMID: 26934656
16. We show that elevated levels of PPARG strongly correlate with elevation of FASN in human prostate cancer (CaP) and that high levels of PPARG/FASN and PI3K/pAKT pathway activation confer a poor prognosis.These data suggest that CaP patients could be stratified in terms of PPARG/FASN and PTEN levels to identify patients with aggressive CaP who may respond favorably to PPARG/FASN inhibition. PMID: 27357679
17. High FASN expression is associated with meningioma and schwannoma. PMID: 28729415
18. our findings show that microRNA-195 inhibits pancreatic cancer cell proliferation and invasion by regulating the fatty acid synthase/Wnt signaling pathway, suggesting a tumor suppressive role for microRNA-195 in the development and progression of pancreatic cancer. Thus, inhibiting fatty acid synthase by microRNA-195 may serve as a novel therapeutic approach for the treatment of pancreatic cancer. PMID: 28639885
19. Inhibition of FASN can decrease the levels of IGFBP1, and the expression, activity, and ubiquitination of HIF-1alpha. Inhibition of FASN can suppress migration, invasion and healing of hepatoma carcinoma cells by decreasing HIF-1alpha, and IGFBP1. PMID: 28197637
20. The involvement of SREBP-1c and ChREBP in FASN promoter histone modification.Histone acetylation affects FASN transcription by influencing ChREBP-binding carbohydrate-responsive elements. PMID: 28027934
21. Fatty acid synthase (FASN) inhibitors reduce proliferation and promote apoptosis in high FASN producers lymphatic endothelial cells (HDLEC) cells. PMID: 27918556
22. MACC1 and FASN are positively correlated and responsible for the poor prognoses in gastric cancer patients.FASN role in gastric cancer resistance to oxaliplatin. PMID: 28339092
23. Fatty acid synthase fine-tunes the cell's response to stress and injury by remodeling cellular O-GlcNAcylation PMID: 28232487
24. B7-H3 hijacks SREBP-1/FASN signaling mediating abnormal lipid metabolism in lung cancer PMID: 27939887
25. Uterine leiomyomata risk was positively associated with FASN AA genotype of SNP rs4247357 among the 7% of African American women with >40% European ancestry. PMID: 27375065
26. DNA methylation in HIF3A shares moderate correlation between adipose tissue and blood, and both are associated with BMI. In contrast, methylation in FASN is poorly correlated across tissues, but the DNA methylation in adipose tissue but not blood is highly associated with BMI PMID: 26891033
27. the present study provided evidence that miR320 may directly target fatty acid synthase. These results suggest that miR320 may serve as a therapeutic biomarker of NSCLC in the future. PMID: 27277534
28. increased expression of NF-YA may promote a malignant phenotype in OS cells via modulation of FASN expression. PMID: 27840951
29. Results suggest investigation of combined fatty acid synthase (FASN) inhibition and taxane treatment as a therapy for a variety of cancers. PMID: 28159572
30. our study suggests that miR12075p/FASN plays an important role in hepatocellular carcinoma PMID: 27461404
31. Our observations suggest a physiological role of placental FASN in human pregnancy. Future studies will clarify whether circulating FASN of placental origin does actually regulate placental and fetal growth PMID: 27090298
32. Results suggest that FASN plays a pivotal role in glioma neovascularization, and inhibition of FASN may be a potential target for anti-angiogenic therapy for glioma. PMID: 27601165
33. The role of FASN in breast cancer [review] PMID: 26951539
34. FASN, ErbB2-high-expressing SK-BR-3 cells displayed higher levels of glycolysis and migration than FASN, ErbB2-low-expressing MCF7 cells. PMID: 26936618
35. S-nitrosylation of FAS at normal physiological levels of NO increases its activity through dimerization and may contribute to the proper regulation of adipogenesis PMID: 26851298
36. concluded that EGFR can be activated intracellularly by FASN-dependent palmitoylation PMID: 26378037
37. Our results suggest that FASN upregulation and PTEN downregualtion may be involved in peritoneal dissemination for gastric cancer progression. PMID: 26514456
38. Data suggest that thioesterase 2 (TE2) catalytic domain of FASN exhibits novel capping domain insert within the alpha/beta hydrolase core; TE2 (as opposed to TE1 domain) readily releases short chain fatty acids from full-length FASN during turnover. PMID: 26663084
39. data demonstrate that selective and potent FASN inhibition with TVB-3166 leads to selective death of tumor cells, without significant effect on normal cells, and inhibits in vivo xenograft tumor growth at well-tolerated doses. PMID: 26425687
40. Results showed correlated FASN regulation relative to key signaling genes with tumor invasion and differentiation in primary retinoblastoma (RB) tissues. Its silencing exerted definite anti-cancer effects in RB cells through PI3K/AKT signaling pathway. PMID: 25958981
41. Findings indicate that overexpression of FASN plays a crucial role in maintaining energy homeostasis in CRC via increased oxidation of endogenously synthesized lipids. PMID: 25970773
42. TG levels are regulated by HCBP6-sterol regulatory element binding protein 1c (SREBP1c)-mediated fatty acid synthase (FASN) expression. PMID: 25855506
43. Loss of fatty acid synthase suppresses the malignant phenotype of colorectal cancer cells by down-regulating energy metabolism and mTOR signaling pathway. PMID: 26109148
44. In the present study it was determined whether three key enzymes for glycolysis, glutaminolysis and de novo synthesis of FAs, hexokinase-2, glutaminase and fatty acid synthase PMID: 26134042
45. FASN and HER2 have roles in breast cancer and are blocked by EGCG with pertuzumab or temsirolimus PMID: 26107737
46. Overall, no SNPs were associated with any known aggressiveness indicators. FASN staining intensity was stronger in malignant than in benign tissue, and NADT was associated with decreased FASN staining in both benign and malignant tissue PMID: 25868764
47. The results suggested that differential levels of P-glycoprotein, Caveolin-1 and Fatty acid synthase except CYP450 play a major role in acquired resistant phenotype in bladder cancer. PMID: 26025399
48. FASN inhibition induced apoptosis in chemosensitive and platinum-resistant ovarian cancer cells and may reverse cisplatin resistance. PMID: 25947066
49. These results for the first time indicated that a cross talk in FASN and HER2 expressions might be associated with prognosis in malignant ovarian cancer. PMID: 25433947
50. The results reveal that the cytotoxic effects of FASN inhibitors in sensitive lines may be due to the robust depletion of oncogenic signaling lipids, such as diacylglycerols and the elevation of tumor-suppressing ceramides. PMID: 25871544
顯示更多

收起更多
亞細胞定位：

Cytoplasm. Melanosome. Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV.
組織特異性：

Ubiquitous. Prominent expression in brain, lung, liver and mammary gland.
數據庫鏈接：

HGNC: 3594

OMIM: 600212

KEGG: hsa:2194

STRING: 9606.ENSP00000304592

UniGene: Hs.83190

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human
VIM Recombinant Monoclonal Antibody

Applications: ELISA, IHC, IF

Species Reactivity: Human
VDR Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human